At a glance
ClinicalIndex Comparison RecordN/AUnknown· 50 target
Drug / intervention
Paclitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NSABP Biospecimen Discovery Project
In Brief
An observational study evaluating Paclitaxel, trastuzumab, and 1 other intervention for Breast Cancer. Targeting 50 participants across 5 sites.
Detailed Summary
This study is a biospecimen discovery project that will serve as a pilot for a comprehensive 'omics approach using fresh core biopsy tissue and blood samples for DNA and protein analysis, as well as paired tumor-normal exome DNA and RNA sequencing.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Timeline
N/AUnknownOverdue
20132014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartJul 2013
Primary CompletionJun 2018
Study CompletionFeb 2022
TodayJul 2026
First PostedMay 9, 2013
Enrollment StartJul 1, 2013
Primary CompletionJun 1, 2018
Study CompletionFeb 1, 2022
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 13.1 years ago
Interventions
Paclitaxeldrug
trastuzumabbiological
pertuzumabbiological